Pre-Clinical and Clinical Laboratories
MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company.
Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Our platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches.
Our portfolio includes:
MD Biosciences as a Preclinical Service Provider
- Our fee-for-service model is provided selectively, and includes in vitro assays and screens, in vivo efficacy studies, determination of PK, pre-toxicity and approximation of the mode of action.
MD Biosciences as a Clinical Biomarker Diagnostic Laboratory
- MD Biosciences CLIA services include full clinical chemistry and hematology, biomarker validation, assay development and proprietary cancer markers; specifically in the area of gastro-intestinal carcinomas.
MD Biosciences as a Product Resource
- We develop monoclonal antibodies, proteins and assays resources. Our manufactured products are sold online at mdbioproducts.com and distributed globally.
MD Biosciences Innovalora, Your Drug Development Partner
- MD Biosciences Innovalora engages in collaborative drug development programs in the hit to lead research stage. Current drug development approaches include novel analgesics and cancer therapeutic programs.
MD Biosciences as an Investor
- Utilizing our investment arm we offer risk-sharing investment opportunities for development programs. We invest jointly with Venture Capital companies, private investors, academia and other pharma development companies to assist in moving promising programs forward.